Clinical Trial Update: Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) [Phase 2]

View source ↗

Summary

This is a Phase 2 update on the safety and pharmacokinetics of once-monthly oral islatravir (MK-8591). The MK-8591-016 trial studied participants at low risk of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (MK-8591) (islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-03-21